Regencell Net Income from 2010 to 2026

RGC Stock  USD 26.80  1.48  5.23%   
Regencell Bioscience's Net Loss is decreasing over the years with slightly volatile fluctuation. Overall, Net Loss is projected to go to about -3.1 M this year. During the period from 2010 to 2026 Regencell Bioscience Net Loss annual values regression line had coefficient of variation of  125.36 and r-squared of  0.56. View All Fundamentals
 
Net Loss  
First Reported
2002-06-30
Previous Quarter
-1.9 M
Current Value
-1.7 M
Quarterly Volatility
33.2 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 335.8 K, Interest Expense of 19.8 K or Selling General Administrative of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6 K. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
  
Build AI portfolio with Regencell Stock
Check out the analysis of Regencell Bioscience Correlation against competitors.
Analyzing Regencell Bioscience's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Regencell Bioscience's current valuation and future prospects.

Latest Regencell Bioscience's Net Income Growth Pattern

Below is the plot of the Net Income of Regencell Bioscience Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Regencell Bioscience financial statement analysis. It represents the amount of money remaining after all of Regencell Bioscience Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Regencell Bioscience's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regencell Bioscience's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (3.58 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Regencell Net Income Regression Statistics

Arithmetic Mean57,145,864
Coefficient Of Variation125.36
Mean Deviation66,021,053
Median(390,990)
Standard Deviation71,635,835
Sample Variance5131.7T
Range177.8M
R-Value(0.75)
Mean Square Error2381.2T
R-Squared0.56
Significance0.0005
Slope(10,662,916)
Total Sum of Squares82107.1T

Regencell Net Income History

2026-3.1 M
2025-3.2 M
2024-3.6 M
2023-4.3 M
2022-5.9 M
2021-7.4 M
2020-1.3 M

Other Fundumenentals of Regencell Bioscience

Regencell Bioscience Net Income component correlations

About Regencell Bioscience Financial Statements

Regencell Bioscience stakeholders use historical fundamental indicators, such as Regencell Bioscience's Net Income, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Regencell Bioscience's assets and liabilities are reflected in the revenues and expenses on Regencell Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Regencell Bioscience Holdings. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-3.2 M-3.1 M
Net Loss-3.9 M-4.1 M
Net Loss-6.7 M-6.4 M
Net Loss(0.01)(0.01)
Net Income Per E B T 0.89  0.78 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:
Check out the analysis of Regencell Bioscience Correlation against competitors.
You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.01)
Return On Assets
(0.33)
Return On Equity
(0.55)
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.